1Gabrilovich DI,Corak J.Ciernik IF,et al.Decreased antigen presentation by dendritic cells in patients with breast cancer[J].Clinical Cancer Research,1997,3(3):483-490.
2Hemando JJ,Park TW,Kuhn WC.Dendritic cell-based vaccines in breast and gynaecologic cancer[J].Anticancer Res,2003,23(5b):4293-4303.
3Elkord E,Williams PE,Kynaston H,et al.Differential CTLs specific for prostate-specific antigen in healthy donors and patients with prostate cancer[J].Int Immunol.2005,17(10):1315-1325.
6Morse MA,Nair SK,Mosca PJ,et al.Immunotherapy with autologous,human dendritic cells transfected with carcinoembryonic antigen mRNA[J].Cancer Invest,2003,21(3):341-349.
7Zum Buschenfelde CM,Metzger J,Hermann C,et al.The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells[J].Journal of Immunology,2001,167(3):1712-1721.
8Medin JA,Liang SB,Hou JW,et al.Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo[J].Cancer Gene Ther.2005;12(6):540-551.
9Willis RA,Bowers WJ,Turner MJ,et al.Dendritic cells transduced with HSV-1 amplicons expressing prostate-specific antigen generate antitumor immunity in mice[J].Hum Gene Ther,2001,12(15):1867-1879.
10Mincheff M,Zoubak S,Altankova I,et al.Human dendritic cells genetically engineered to express cytosolically retained fragment of prostate-specific membrane antigen prime cytotoxic T-cell responses to multiple epitopes[J].Cancer Gene Ther,2003,10(12):907-917.
2Liu Y, Chiriva-Internati M, You C, et al. Use and specificity of breast cancer antigen/milk protein BA46 for generating anti-selfcytotoxic T lymphocytes by recombinant adeno-associated virusbased gene loading of dendritic cells [ J ]. Cancer Gene Ther,2005,12(3) :304 - 312.
3Midgley R, Kerr DJ, Mirza N, et al. A phase Ⅱ dendritic cell (DC) immunotherapy trial for hepatocellular carcinoma (HC) [J]. Proc Am Soc Clin Oncol,2002,21:23b.
4Chang JWC,Hsieh JJ,Chen J S, et al. Immunotherapy with dendritic cells pulsed by autologous dactinomycin-treated melanoma apoptotic cells for patients with malignant melanoma [ J ]. ProcAm Soc Clin Oncol,2002,21:3b.
5Chiriva-Internati M, Liu Y, Salati E, et al. Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells[J ]. Eur J Immunol, 2002,32(1) :30 - 38.
6Slichenmyer WJ,Fry DW. Anticancer therapy targeting the erbB family of receptor tyrosine kinases[J]. Semin Oncol, 2001,28 (Suppl 16) :S67 - S79.
7Hainsworth JD, Litchy S, Burris HA, et al. Rituximab as firstline and maintenance therapy for patients with indolent nonhodgkin's lymphoma[J]. J Clin Oncol,2002,20(20):4261 -4267.
8Cohen RB. Epidermal growth factor receptor as a therapeutic target in colorectal cancer[J]. Clin Colorectal Cancer ,2003,2(4): 246 - 251.
9Goodman L. Persistance-luck-Avastin[J]. J Clin Invest,2004, 113(7) :934 - 940.
10Van Oosterom AT, Judson I, Verweij J, et al. STI 571, an active drug in metastatic gastro-intestinal stromal tumors (GIST), an EORTC phase Ⅰ study[J]. Proc Am Soc Clin Oncol,2001,20 : 1 a.
